ClinicalTrials.gg
RecruitingNCT06613204STELLA-FTDUpdated Oct 27, 2025

STELLA-FTD: Examination of a Behavior Change Intervention for FTD Family Care Partners

An interventional study of STELLA-FTD Control and STELLA-FTD Test in Frontotemporal Dementia, Caregiver Burden and Primary Progressive Aphasia (PPA), sponsored by Oregon Health and Science University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-27.

Sponsored by Oregon Health and Science University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
640
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Frontotemporal Dementia with a site in United States — 31 open to participants now, 45 under way, none of them phase 3. Frontotemporal Dementia · United States.

Planned enrollment
7th of 66
640 · median 60
Started
2025
with 5 others
No phase
31 of 103
11 open now
Primary completion
2029-06
later than 30 of 44 live
Registered
93rd of 103
by date

Among the 103 studies in Frontotemporal Dementia with a site in United States, this one is the 7th largest by planned enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2025, is one of 31 with no phase, reaches primary completion later than 30 of the 44 other live ones, and was the 93rd registered.

Frontotemporal Dementia

208 studies on the registry are indexed under Frontotemporal Dementia; 72 are open to participants now.

Browse Frontotemporal Dementia studies →

Open to participants now

31 of the 103 studies in Frontotemporal Dementia with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Frontotemporal Dementia studies recruiting now, 29 (57%) set no upper age limit and 5 (10%) stop at 75 or younger; 6 take children under 18; 30 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Frontotemporal Dementia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this nationwide study is to test STELLA-FTD (Support via Telehealth: Living and Learning with Advancing Alzheimer's Disease)-FTD, an intervention to specifically address the needs of family Care Partners of persons with frontotemporal degeneration (FTD). STELLA-FTD is a multicomponent videoconference-based intervention designed to facilitate effective use of community and peer resources to foster effective management of behavioral and psychological symptoms of dementia. The study is recruiting families from across the United States.

Read the detailed description

The study will enroll a total sample of up to 640 participants: 320 family Care Partners and their 320 Care Recipients with FTD. For our study "family Care Partner" includes any person who is considered "family" to the person with FTD, such as direct relations, fictive kin, close friends and neighbors. "Care Recipient" is defined as an individual with an FTD diagnosis noted by the AFTD: bv-FTD, PPA, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), or ALS with FTD. Care Recipients with FTD will not participate in intervention but will be consented (and thus enrolled) because data will be collected about them. The study will test to see if our program helps Care Partners.

The STELLA-FTD intervention is delivered over 8 sessions within 10 consecutive weeks in 1-hour "live" video-based group sessions led by two guides. There will be two intervention groups, the control group and the test group. There will be up to 8 Care Partners per group, which allows for the development of mutual trust and commitment.

Care Partners will be randomized to either the test or control group using an electronic randomization process and will be blinded to their group designation. Both groups will receive information and support (via videoconferencing). The test group will receive a different program than the control group. Care Partners will fill out 6 long surveys while in the study, and a brief weekly survey.

03

Conditions studied

  • Frontotemporal Dementia
  • Caregiver Burden
  • Primary Progressive Aphasia (PPA)
  • Corticobasal Syndrome

Keywords

  • behavioral intervention
  • FTD
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Family Care Partner

  • Adult caring for family member with FTD.
  • Provides 4 or more hours of care/week. Does not have to reside with.
  • Identifies at least 2 moderately upsetting behaviors in the person with FTD.
  • Speaks and understands English to be able to participate in intervention.
  • Owns a telephone (smartphone, cell phone or landline).
  • Has email and mailing address to receive computer, study materials and surveys.
  • Provides to participate in the research.
  • Lives in the US

Inclusion Criteria: Person with FTD

  • Diagnosis of FTD
  • Family member of a Care Partner (this can be a relative, spouse, or close kin that is considered family).
  • Lives in US

Exclusion Criteria: Person with FTD

  • No Frontotemporal Degeneration diagnosis.
  • Unable to leave Care Partner during STELLA-FTD sessions.
  • Enrolled in hospice.

Exclusion Criteria: Family Care Partner

  • Unable to find activity for Care Recipient during STELLA-FTD sessions to allow Care Partner to work privately with Guide and other Care Partners.
  • Hearing and/or vision problems severe enough to prevent participation.
  • Refuses to be video-recorded during STELLA-FTD sessions.
  • Unwilling or unable to adequately follow study instructions and participate in study procedures.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
640 participants (estimated)

Study arms

  • Active comparator
    Control Group

    Control group, receives information and support in a group setting (N=160 Care Partners).

    Behavioral: STELLA-FTD Control

  • Experimental
    Test Group

    Test group, receives information and support in a group setting, but program is different from control (N=160 Care Partners).

    Behavioral: STELLA-FTD Test

  • No intervention
    Care Recipients with FTD

    Care recipients are consented to inform them of their rights, but they do not take part in any activities (N=320 Care Recipients).

Interventions

  • BehavioralSTELLA-FTD Control

    Participants receive information about FTD and support via weekly group video-conference-based meetings.

  • BehavioralSTELLA-FTD Test

    The test group receives a information and support, but with a focus that is different from the Control Group

06

What researchers measure

Primary outcomes

  1. Revised Memory and Behavior Problems Checklist, Frequency, Original Scale

    Efficacy will be assessed by measuring pre/post changes on the RMBPC. The RMBPC is a 24-item caregiver report measure, 5-point Likert scale with higher scores on frequency indicate more upsetting behaviors Frequency range is 0 (never occurred) to 4 (daily or more often). Frequency score range is 0 to 96

    Time frame: 1 month pre-intervention; 1 week pre-intervention, 4 weeks after intervention start; 8 week post intervention; 2 and 6 months post intervention

  2. Revised Memory and Behavior Problems Checklist, Reactivity, Original Scale

    Efficacy will be assessed by measuring pre/post changes on the RMBPC. The RMBPC is a 24-item caregiver report measure, 5-point Likert scale with higher scores on reactivity indicate more Care Partner burden. Frequency range is 0 (no burden) to 4 (high burden). Frequency score range is 0 to 96

    Time frame: 1 month pre-intervention; 1 week pre-intervention, 4 weeks after intervention start; 8 week post intervention; 2 and 6 months post intervention

Secondary outcomes

  1. Self-efficacy for symptom management and support service use

    10-item scale to measure self-efficacy. Assesses caregiver certainty that they will use services and support programing. 1= not at all certain, to 10=very certain. Scores range from 10 to 100, with 100 being high certainty.

    Time frame: 1 month pre-intervention; 1 week pre-intervention, 8 week post intervention; 2 and 6 months post intervention

  2. Neuropsychiatric Inventory-Caregiver Self-efficacy Scale

    Measures frequency of behaviors related to frontotemporal dementia and Care Partner confidence in managing behaviors. Frequency is rated on a scale of 1 (occasionally) to 4 (very frequently), severity is rated from 1 (mild) to 3 (severe), and caregiver distress is rated from 0 (no distress) to 5 (extreme or very severe). Total scores are calculated by multiplication of the frequency and severity for each symptom and the addition of all item scores, with a range of 0-144. The distress score total is calculated by the sum of all the individual domain scores, with a range of between 0 and 60. If a behavioral symptom is noted, the care partner is asked to about how confident they are in addressing it, Responses range from 4 (not at all confident), 3 (fairly confident), 2 (confident), and 1 (very confident).

    Time frame: 1 month pre-intervention; 1 week pre-intervention, 8 week post intervention; 2 and 6 months post intervention

  3. Preparedness for Caregiving Scale

    10-item measure that assesses how prepared care partners feel to care for their family member with dementia. Ranges from 0 (not at all prepared) to 40 (very well prepared).

    Time frame: 1 month pre-intervention; 1 week pre-intervention, 8 week post intervention; 2 and 6 months post intervention

  4. Personalized Target Behavior Survey

    On STELLA-FTD Website, measures frequency and reactivity of up to 3 personalized behaviors identified by Care Partners. Care partners rate how often the 5-point Likert scale with higher scores on frequency indicate more upsetting behaviors Frequency range is 0 (never occurred) to 4 (daily or more often). Frequency score range is 0 to 4 for each Target behavior. Higher scores indicate higher frequency and burden.

    Time frame: 1 week pre-intervention, 8 week post intervention

  5. Service and Support use survey

    10-item survey that queries participants about service use. Score is not on a scale.

    Time frame: 1 month pre-intervention; 1 week pre-intervention, 8 week post intervention; 2 and 6 months post intervention

  6. Support via Telehealth: Living and Learning with Advancing Frontotemporal Dementia Experience Survey

    18-item- survey on satisfaction, privacy, ease of use. Scores range from 1 (strongly disagree) to 5 (strongly agree). Total score ranged 18-90, higher scores are better

    Time frame: 1 week post intervention

  7. Orbit Survey

    Weekly survey of burden, service use, medication use. Score is not on a scale.

    Time frame: Weekly, starts at Week 1, ends after week 36.

  8. Revised Memory and Behavior Problem Checklist Frontotemporal Degeneration Supplement, Frequency

    Measures frequency of upsetting frontotemporal behaviors. 9 items, scores range from 0 (no behaviors) to 36 (all behaviors)

    Time frame: 1 month pre-intervention; 1 week pre-intervention, 4 weeks after intervention start; 8 week post intervention; 2 and 6 months post intervention

  9. Revised Memory and Behavior Problem Checklist Frontotemporal Degeneration Supplement, Reactivity

    Measures caregivers reactions to upsetting frontotemporal behaviors. 9 items, scores range from 0 (no reactivity) to 36 (high reactivity)

    Time frame: 1 month pre-intervention; 1 week pre-intervention, 4 weeks after intervention start; 8 week post intervention; 2 and 6 months post intervention

  10. Clinical Dementia Rating Scale plus Frontotemporal Lobar Degeneration

    This is an 8-item survey that assesses disease severity, with 0=no impairment to 3=severe impairment. Range is 0-24 (Sum of boxes)

    Time frame: One time assessment at enrollment

  11. Ten Item Personality Inventory

    10 items that assess personality type. Respondents note how they agree with each. personality type, from 1=Disagree strongly 2 = Disagree moderately 3 = Disagree a little 4 = Neither agree nor disagree 5 = Agree a little 6 = Agree moderately 7 = Agree strongly Score is not on a scale.

    Time frame: Once, at Week 1 of intervention

  12. Contact Survey

    Nine questions query caregivers about if they contacted other caregivers in the study, and, if so, how often. Score is not on a scale

    Time frame: Week 13, 20, and 36

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Lindauer A, Smith S, Gothard S, Mattek N, Tran L, Mooney A. 'There's no straight line...' a consumer-informed intervention for FTD family care partners: the STELLA-FTD pilot study. Aging Ment Health. 2023 Sep-Oct;27(10):2000-2010. doi: 10.1080/13607863.2023.2250741. Epub 2023 Sep 1. PubMed 37655616 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Aggregated data for journal articles and presentations, IPD via data request to OHSU

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: 2/15/2025-7/14/2029

Access criteria: Scientists can contact our center to request data

Data sharing details ↗ · www.ohsu.edu

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2029, 48 months after the start.

Of 51 non-industry interventional studies with no phase under Frontotemporal Dementia, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 97. This study's planned 48 months is above that.

Counting every sponsor, half of 54 studies reached it within 41 months; a quarter within 21 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2024
First posted
Sep 25, 2024
StartActual
Jun 23, 2025
Primary completionEst.
Jun 2029
CompletionEst.
Jun 2029
Last update
Oct 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06613204
Responsible party
Allison Lindauer (Associate Professor, Oregon Health and Science University) — Principal investigator
First posted
Sep 25, 2024
Start date
Jun 23, 2025
Primary completion
Jun 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Oct 27, 2025

Study contacts

Hailey Chatterton, MS
Contact
chatterton@ohsu.edu
503-568-9725
Allison Lindauer, PhD, APRN
Contact
lindauer@ohsu.edu
503-494-6976
Allison Lindauer, PhD, APRN
principal investigator · Oregon Health and Science University
Aimee Mooney, MA, CCC-SLP
study director · Oregon Health and Science University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion